Buchumschlag

Complete and durable remission of human epidermal growth factor receptor 2-positive metastatic urothelial carcinoma following third-line treatment with trastuzumab and gemcitabine

Urothelial carcinoma (UC) is one of the most common cancers and survival rates are low in metastatic disease with currently established first-line platinum-based chemotherapies. Unlike in many other cancers, no clinically established molecular targeted therapies exist for the treatment of this malig...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Wezel, Felix (VerfasserIn) , Erben, Philipp (VerfasserIn) , Gaiser, Timo (VerfasserIn) , Budjan, Johannes (VerfasserIn) , Hardenberg, Jost von (VerfasserIn) , Michel, Maurice Stephan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: January 2018
In: Urologia internationalis
Year: 2018, Jahrgang: 100, Heft: 1, Pages: 122-125
ISSN:1423-0399
DOI:10.1159/000443280
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000443280
Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/443280
Volltext
Verfasserangaben:Felix Wezel, Philipp Erben, Timo Gaiser, Johannes Budjan, Jost von Hardenberg, Maurice Stephan Michel, Christian Bolenz
Beschreibung
Zusammenfassung:Urothelial carcinoma (UC) is one of the most common cancers and survival rates are low in metastatic disease with currently established first-line platinum-based chemotherapies. Unlike in many other cancers, no clinically established molecular targeted therapies exist for the treatment of this malignancy. Here we present a case of complete tumor remission following third-line treatment with trastuzumab and gemcitabine in a patient with human epidermal growth factor receptor 2 (HER2)-positive UC after progression under cisplatin and vinflunine chemotherapies. This case shows the potential significance of anti-HER2 therapy in selected patients with molecularly characterized UC. Clinical trials so far show inconclusive outcomes of anti-HER2 therapies in UC, indicating further need for both basic research and clinical studies for the identification of resistance factors and improved patient selection.
Beschreibung:Gesehen am 21.04.2020
Beschreibung:Online Resource
ISSN:1423-0399
DOI:10.1159/000443280

Ähnliche Einträge